Additional benefit for sleep apnea sufferers
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.
Using data from the Sleep Apnea Cardiovascular Endpoints (SAVE) trial led by Flinders University, the new study has found a significant decrease in cases of depression after patients received CPAP treatment for their sleep apnea.
This is by far the largest trial of its type and one of very few studies reporting such an effect, says Professor Doug McEvoy from Flinders University.
From detailed analysis of the SAVE data, Flinders University experts and collaborators at the George Institute have found that CPAP for moderate-severe OSA in patients with cardiovascular disease has broader benefits in terms of preventing depression, independent of improved sleepiness.
Prior studies investigating the effect of CPAP on mood with various experimental designs and length of follow-up periods have yielded heterogenous results.
“Patients who have had a stroke or heart attack are prone to suffer from low mood and are 2 to 3 times more likely to develop clinical depression, which then further elevates their risk of future heart attacks and strokes,” says SAVE principal investigator Professor McEvoy, a senior author in the paper just published by The Lancet in EClinicalMedicine.
With up to 50% of patients with CV disease likely to have OSA, the study is “welcome news that treatment of OSA substantially relieves cardiovascular patients’ depressive symptoms and improves their wellbeing”.
The paper’s first author, Dr Danni Zheng, from the George Institute for Global Health (UNSW), says the 2687 OSA patients enrolled in the SAVE trial were based solely on their history of cardiovascular disease and not on their current mood status.
“After following them for an average of 3.7 years, we found that CPAP provided significant reductions in depression symptoms compared with those who were not treated for OSA. The improvement for depression was apparent within six months and was sustained.”
As expected, those with lower mood scores to start with appeared to get the greatest benefit.
“Our additional systematic review which combined the SAVE study findings with previous work provided further support of the treatment effect of CPAP for depression,” Dr Zheng says.
The paper – “Effects of continuous positive airway pressure on depression and anxiety symptoms in patients with obstructive sleep apnoea: results from the Sleep Apnoea cardiovascular Endpoint randomised trial and meta-analysis”, by Danni Zheng, Ying Xu, Shoujiang You, Maree L. Hackett, Richard J. Woodman, Qiang Li, Mark Woodward, Kelly A. Loffler, Anthony Rodgers, Luciano F. Drager, Geraldo Lorenzi-Filho, Xia Wang, Wei Wei Quan, Manjari Tripathi, Olga Mediano, Qiong Ou, Rui Chen, Zhihong Liu, Xilong Zhang, Yuanming Luo, Nigel McArdle, Sutapa Mukherjee, R. Douglas McEvoy and Craig S. Anderson – has been published in EClinicalMedicine (The Lancet) DOI:https:/
- SAVE trial participants were recruited from more than 80 clinical centres in China, Australia, New Zealand, India, the USA, Spain and Brazil and were predominantly overweight and older males, habitual snorers and had moderately severe OSA.
- The latest study showed a significant fall in depression symptoms in OSA patients after CPAP treatment, independent of improvements in daytime sleepiness.
- The positive effect of CPAP treatment on depression symptoms was manifest within six months and persisted during the 3.7 years of follow-up.
- The positive effect of CPAP treatment on depression symptoms was more pronounced in patients with lower mood scores prior to treatment.